NASDAQ:CDTX • US1717572069
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CIDARA THERAPEUTICS INC (CDTX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-11-18 | Guggenheim | Downgrade | Buy -> Neutral |
| 2025-11-14 | Needham | Downgrade | Buy -> Hold |
| 2025-11-14 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-11-07 | Needham | Maintains | Buy -> Buy |
| 2025-11-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-16 | Morgan Stanley | Initiate | Overweight |
| 2025-10-10 | JP Morgan | Initiate | Overweight |
| 2025-10-09 | WBB Securities | Maintains | Strong Buy -> Strong Buy |
| 2025-10-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-03 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-09-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-25 | Guggenheim | Maintains | Buy -> Buy |
| 2025-09-24 | WBB Securities | Reiterate | Strong Buy -> Strong Buy |
| 2025-09-24 | Needham | Maintains | Buy -> Buy |
| 2025-09-22 | WBB Securities | Maintains | Strong Buy -> Strong Buy |
| 2025-08-08 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-08-08 | Needham | Maintains | Buy -> Buy |
| 2025-08-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-30 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-06-24 | Guggenheim | Maintains | Buy -> Buy |
| 2025-06-24 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-06-23 | WBB Securities | Reiterate | Strong Buy -> Strong Buy |
| 2025-06-23 | Needham | Maintains | Buy -> Buy |
| 2025-06-10 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 64.448M 30.01% | 63.905M -0.84% | 1.275M -98.00% | -100.00% | 8.597M | 10.232M 19.02% | 390.39M 3,715.38% | 824.06M 111.09% | 1.278B 55.09% | 1.662B 30.05% | 2.202B 32.49% | 2.736B 24.25% | |
| EBITDA YoY % growth | -33.36M 20.70% | -24.365M 26.96% | -90.986M -273.43% | -193.951M -113.17% | -238.523M -22.98% | -218.143M 8.54% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -33.503M 20.71% | -24.483M 26.92% | -91.219M -272.58% | -193.804M -112.46% | -207.459M -7.05% | -230.893M -11.30% | 58.888M 125.50% | 386.78M 556.81% | 717.74M 85.57% | 1.071B 49.22% | 1.482B 38.38% | 1.991B 34.35% | |
| Operating Margin | -51.98% | -38.31% | -7,154.43% | N/A | -2,413.16% | -2,256.58% | 15.08% | 46.94% | 56.16% | 64.44% | 67.30% | 72.77% | |
| EPS YoY % growth | -9.60 42.86% | -4.80 50.00% | -11.49 -139.37% | -8.30 27.77% | -6.40 22.83% | -6.48 -1.23% | 0.70 110.80% | 7.44 961.60% | 14.71 97.85% | 23.65 60.78% | 30.04 26.99% | 37.72 25.57% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.54 71.35% | -1.37 17.66% | -1.60 3.25% | -1.89 38.96% | -2.27 -47.49% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -51.255M 4.99% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -48.529M 10.43% | -30.6M -21.10% | -30.6M -11.74% | -31.62M 27.52% | -31.62M 34.84% |
All data in USD
14 analysts have analysed CDTX and the average price target is 220.19 USD. This implies a price decrease of -0.54% is expected in the next year compared to the current price of 221.38.
CIDARA THERAPEUTICS INC (CDTX) will report earnings on 2026-03-04, after the market close.
The consensus EPS estimate for the next earnings of CIDARA THERAPEUTICS INC (CDTX) is -1.54 USD and the consensus revenue estimate is 0 USD.
The consensus rating for CIDARA THERAPEUTICS INC (CDTX) is 74.2857 / 100 . This indicates that analysts generally have a positive outlook on the stock.